Maintenance of supersaturation II: Indomethacin crystal growth kinetics versus degree of supersaturation

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1544-1553

  Patel, Dhaval D ^a,b   Anderson, Bradley D ^a  

^a University of Kentucky   (United States)

^b not available   (United States)

Author keywords

Crystal growth; Diffusion; Indomethacin; Kinetics; Second derivative UV spectroscopy; Solubility; Supersaturation; Surface disorder; Surface energetics; Surface integration; Suspension

Indexed keywords

INDOMETACIN;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG ABSORPTION; DRUG SOLUBILITY; INFUSION RATE; INFUSION SYSTEM; IONIC STRENGTH; PARTICLE SIZE; PH;

EID: 84876344777     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23498     Document Type: Article

References (26)

1. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98(8):2549-2572.
2. Lindfors L, Forssén S, Westergren J, Olsson U. 2008. Nucleation and crystal growth in supersaturated solutions of a model drug. J Colloid Interface Sci 325(2):404-413.
3. Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, Surapaneni S. 2009. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 98(2):516-528.
4. Myerson AS, Ginde R, Allan SM. 2002. Crystals, crystal growth, and nucleation. Handbook of industrial crystallization. 2nd ed. Woburn: Butterworth-Heinemann, p 33-65.
5. Galkin O, Vekilov PG. 1999. Are nucleation kinetics of protein crystals similar to those of liquid droplets? J Am Chem Soc 122(1):156-163.
6. Garside J, Mersmann A, Nývlt J. 2002. Measurement of crystal growth and nucleation rates. 2nd ed. Rugby, UK: Institution of Chemical Engineers (IChemE).
7. Roelands CPM, terHorst JH, Kramer HJM, Jansens PJ. 2006. Analysis of nucleation rate measurements in precipitation processes. Cryst Growth Des 6(6):1380-1392.
8. Mullin JW. 2001. Crystallization. 4th ed. Oxford; Boston: Butterworth-Heinemann.
9. Ohara M, Reid RC. 1973. Modeling crystal growth rates from solution. 1st ed. Englewood Cliffs, New Jersey: Prentice-Hall.
10. Warren DB, Benameur H, Porter CJH, Pouton CW. 2010. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J Drug Target 18(10):704-731.
11. Bennema P. 1969. The importance of surface diffusion for crystal growth from solution. J Cryst Growth 5(1):29-43.
12. Boistelle R, Astier JP. 1988. Crystallization mechanisms in solution. J Cryst Growth 90(1-3):14-30.
13. Patel DD, Joguparthi V, Wang Z, Anderson BD. 2011. Maintenance of supersaturation I: Indomethacin crystal growth kinetic modeling using an online second-derivative ultraviolet spectroscopic method. J Pharm Sci 100(7):2623-2641.
14. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. 1981. Dissolution kinetics of carboxylic-acids. 1. Effect of pH under unbuffered conditions. J Pharm Sci 70(1):13-22.
15. Slavin PA, Sheen DB, Shepherd EEA, Sherwood JN, Feeder N, Docherty R, Milojevic S. 2002. Morphological evaluation of the [gamma]-polymorph of indomethacin. J Cryst Growth 237-239(Part 1):300-305.
16. Saleki-Gerhardt A, Ahlneck C, Zografi G. 1994. Assessment of disorder in crystalline solids. Int J Pharm 101(3):237-247.
17. Chow K, Go J, Mehdizadeh M, Grant D. 1984. Modification of adipic acid crystals: Influence of growth in the presence of fatty acid additives on crystal properties. Int J Pharm 20(1-2):3-24.
18. Ahmed H, Buckton G, Rawlins DA. 1996. The use of isBKmal microcalorimetry in the study of small degrees of amorphous content of a hydrophobic powder. Int J Pharm 130(2):195-201.
19. Mosharraf M, Sebhatu T, Nyström C. 1999. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int J Pharm 177(1):29-51.
20. Elamin AA, Ahlneck C, Alderborn G, Nyström C. 1994. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int J Pharm 111(2):159-170.
21. Murphy D, Rodríguez-Cintrón F, Langevin B, Kelly RC, Rodríguez-Hornedo N. 2002. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int J Pharm 246(1-2):121-134.
22. Li L, Rodríguez-Hornedo N. 1992. Growth kinetics and mechanism of glycine crystals. J Cryst Growth 121(1-2):33-38.
23. Moreno E, Zahradnik R, Glazman A, Hwu R. 1977. Precipitation of hydroxyapatite from dilute solutions upon seeding. Calcif Tissue Int 24(1):47-57.
24. Rodríguez-hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88(7):651-660.
25. Scholl J, Lindenberg C, Vicum L, Mazzotti M, Brozio J. 2007. Antisolvent precipitation of PDI 747: Kinetics of particle formation and growth. Cryst Growth Des 7(9):1653-1661.
26. Nancollas G, Reddy MM, Tsai F. 1973. Calcium sulfate dihydrate cyrstal-growth in aqueous-solution at elevated-temperatures. J Cryst Growth 20(2):125-134.